Olema Pharmaceuticals (OLMA) News Today → Exposed: 10 CENT Crypto to Explode May 20th? (From True Market Insiders) (Ad) Free OLMA Stock Alerts $9.22 -0.10 (-1.07%) (As of 05/13/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 13 at 5:41 AM | americanbankingnews.comFY2028 EPS Estimates for Olema Pharmaceuticals, Inc. Lowered by Analyst (NASDAQ:OLMA)May 13 at 4:52 AM | americanbankingnews.comOlema Pharmaceuticals (NASDAQ:OLMA) PT Raised to $28.00 at HC WainwrightMay 13 at 1:52 AM | americanbankingnews.comLifesci Capital Weighs in on Olema Pharmaceuticals, Inc.'s Q2 2024 Earnings (NASDAQ:OLMA)May 11 at 4:11 AM | americanbankingnews.comLifesci Capital Weighs in on Olema Pharmaceuticals, Inc.'s Q3 2024 Earnings (NASDAQ:OLMA)May 11 at 1:16 AM | americanbankingnews.comOlema Pharmaceuticals, Inc. (NASDAQ:OLMA) Given Average Recommendation of "Buy" by BrokeragesMay 10 at 8:21 AM | marketbeat.comOlema Pharmaceuticals, Inc. Forecasted to Earn Q3 2024 Earnings of ($0.52) Per Share (NASDAQ:OLMA)Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) - Stock analysts at Lifesci Capital issued their Q3 2024 earnings estimates for shares of Olema Pharmaceuticals in a research report issued to clients and investors on Wednesday, May 8th. Lifesci Capital analyst S. Slutsky forecasts that theMay 10 at 12:53 AM | markets.businessinsider.comBuy Rating on Olema Pharmaceuticals Amid Promising Clinical Trials and Strong Financial PositionMay 9, 2024 | markets.businessinsider.comBuy Rating on Olema Pharmaceuticals: Financial Stability and Promising Drug Development Fuel Positive OutlookMay 9, 2024 | americanbankingnews.comCyrus Harmon Sells 5,000 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) StockMay 9, 2024 | markets.businessinsider.comBuy Rating Affirmed on Olema Pharmaceuticals Amid Promising Breast Cancer Treatment Advances and Strategic Novartis CollaborationMay 8, 2024 | investorplace.comOLMA Stock Earnings: Olema Pharmaceuticals Misses EPS for Q1 2024May 8, 2024 | globenewswire.comOlema Oncology Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 8, 2024 | globenewswire.comOlema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual CongressMay 8, 2024 | insidertrades.comOlema Pharmaceuticals, Inc. (NASDAQ:OLMA) Director Cyrus Harmon Sells 5,000 SharesMay 4, 2024 | americanbankingnews.comCyrus Harmon Sells 15,000 Shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) StockMay 3, 2024 | insidertrades.comOlema Pharmaceuticals, Inc. (NASDAQ:OLMA) Director Sells $142,650.00 in StockMay 2, 2024 | marketbeat.comOlema Pharmaceuticals, Inc. (NASDAQ:OLMA) Director Cyrus Harmon Sells 15,000 SharesOlema Pharmaceuticals, Inc. (NASDAQ:OLMA - Get Free Report) Director Cyrus Harmon sold 15,000 shares of the stock in a transaction on Tuesday, April 30th. The shares were sold at an average price of $9.51, for a total value of $142,650.00. Following the completion of the sale, the director now owns 811,283 shares of the company's stock, valued at $7,715,301.33. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.May 2, 2024 | globenewswire.comOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 1, 2024 | globenewswire.comOlema Oncology to Participate in Upcoming Investor Conferences in MayApril 21, 2024 | finance.yahoo.comOlema Pharmaceuticals, Inc. (OLMA)April 18, 2024 | marketbeat.comOlema Pharmaceuticals (NASDAQ:OLMA) Stock Price Down 6.2%Olema Pharmaceuticals (NASDAQ:OLMA) Stock Price Down 6.2%April 12, 2024 | markets.businessinsider.comBuy Rating on Olema Pharmaceuticals Amidst Promising Oncology Developments and Competitive EdgeApril 10, 2024 | bizjournals.comHow Olema Oncology moved from layoffs to pivotal cancer drug studiesApril 8, 2024 | globenewswire.comOlema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual ConferenceApril 2, 2024 | globenewswire.comOlema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 2, 2024 | marketbeat.comOlema Pharmaceuticals (NASDAQ:OLMA) Shares Gap Up to $10.89Olema Pharmaceuticals (NASDAQ:OLMA) Shares Gap Up to $10.89April 2, 2024 | marketbeat.comOlema Pharmaceuticals (NASDAQ:OLMA) Coverage Initiated by Analysts at The Goldman Sachs GroupThe Goldman Sachs Group assumed coverage on Olema Pharmaceuticals in a report on Tuesday. They issued a "buy" rating and a $24.00 price objective for the company.April 1, 2024 | marketbeat.comOlema Pharmaceuticals (NASDAQ:OLMA) Shares Down 5.4% After Insider SellingOlema Pharmaceuticals (NASDAQ:OLMA) Trading Down 5.4% on Insider SellingMarch 30, 2024 | insidertrades.comOlema Pharmaceuticals, Inc. (NASDAQ:OLMA) Director Sells $219,400.00 in StockMarch 29, 2024 | marketbeat.comInsider Selling: Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) Director Sells 20,000 Shares of StockOlema Pharmaceuticals, Inc. (NASDAQ:OLMA - Get Free Report) Director Cyrus Harmon sold 20,000 shares of the business's stock in a transaction that occurred on Thursday, March 28th. The shares were sold at an average price of $10.97, for a total value of $219,400.00. Following the completion of the sale, the director now directly owns 826,283 shares of the company's stock, valued at approximately $9,064,324.51. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.March 28, 2024 | seekingalpha.comPalazestrant's Journey: Olema Pharmaceuticals' Long Oncology PathMarch 19, 2024 | marketbeat.comOlema Pharmaceuticals (NASDAQ:OLMA) Stock Price Up 6.9%Olema Pharmaceuticals (NASDAQ:OLMA) Shares Up 6.9%March 16, 2024 | finance.yahoo.comOLMA Jul 2024 12.500 callMarch 16, 2024 | finance.yahoo.comOLMA Apr 2024 22.500 callMarch 15, 2024 | ca.finance.yahoo.comOLMA Oct 2024 25.000 callMarch 15, 2024 | ca.finance.yahoo.comOLMA Oct 2024 10.000 putMarch 14, 2024 | marketbeat.comOlema Pharmaceuticals, Inc. (NASDAQ:OLMA) Short Interest Down 21.2% in FebruaryOlema Pharmaceuticals, Inc. (NASDAQ:OLMA - Get Free Report) was the target of a significant decline in short interest in February. As of February 29th, there was short interest totalling 4,870,000 shares, a decline of 21.2% from the February 14th total of 6,180,000 shares. Based on an average daily volume of 825,000 shares, the short-interest ratio is presently 5.9 days.March 14, 2024 | marketbeat.comFY2024 EPS Estimates for Olema Pharmaceuticals, Inc. Lifted by Analyst (NASDAQ:OLMA)Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) - Analysts at Capital One Financial increased their FY2024 EPS estimates for Olema Pharmaceuticals in a research note issued to investors on Tuesday, March 12th. Capital One Financial analyst N. Quibria now anticipates that the company willMarch 13, 2024 | marketbeat.comOlema Pharmaceuticals (NASDAQ:OLMA) Stock Price Up 11.9%Olema Pharmaceuticals (NASDAQ:OLMA) Stock Price Up 11.9%March 13, 2024 | msn.com3 Best Stocks to Buy Now, 3/13/2024, According to Top AnalystsMarch 13, 2024 | marketbeat.comPolar Capital Holdings Plc Takes $9.26 Million Position in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)Polar Capital Holdings Plc bought a new stake in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 750,000 shares of the company's stock, valued at approximately $9,2March 13, 2024 | marketbeat.comHC Wainwright Comments on Olema Pharmaceuticals, Inc.'s Q1 2024 Earnings (NASDAQ:OLMA)Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) - Analysts at HC Wainwright issued their Q1 2024 earnings per share estimates for shares of Olema Pharmaceuticals in a research report issued on Tuesday, March 12th. HC Wainwright analyst E. Bodnar anticipates that the company will post earnMarch 12, 2024 | markets.businessinsider.comBuy Rating Justified for Olema Pharmaceuticals Amidst Promising Trial Results and Significant Market OpportunityMarch 12, 2024 | markets.businessinsider.comBuy Rating for Olema Pharmaceuticals Based on Promising Palazestrant and Ribociclib Combination in ER+ Breast Cancer TreatmentMarch 12, 2024 | marketbeat.comOlema Pharmaceuticals (NASDAQ:OLMA) Shares Down 8% Olema Pharmaceuticals (NASDAQ:OLMA) Trading Down 8%March 12, 2024 | markets.businessinsider.comStrong Clinical Progress and Market Potential: Buy Rating for Olema Pharmaceuticals’ PalazestrantMarch 11, 2024 | globenewswire.comOlema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate UpdateMarch 11, 2024 | marketbeat.comAdage Capital Partners GP L.L.C. Has $4.80 Million Holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)Adage Capital Partners GP L.L.C. increased its position in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 68.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 388,982 shares of the company's stockMarch 6, 2024 | markets.businessinsider.comBuy Rating for Olema Pharmaceuticals’ Palazestrant Based on Dual Action Efficacy and Strategic Compatibility in ER+ Breast Cancer TreatmentMarch 6, 2024 | finance.yahoo.comOlema Oncology Announces Publication of Data Highlighting Palazestrant’s Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors Get Olema Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for OLMA and its competitors with MarketBeat's FREE daily newsletter. Email Address The 2024 Gold Rush: Unleashing Market Potential (Ad)Welcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights. Get your free information kit NOW, before it's too late. OLMA Media Mentions By Week OLMA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OLMA News Sentiment▼0.640.57▲Average Medical News Sentiment OLMA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OLMA Articles This Week▼233▲OLMA Articles Average Week Get Olema Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for OLMA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: GHRS News STOK News CALT News ZYME News PHAR News LYEL News ORIC News PHAT News SLN News CVAC News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OLMA) was last updated on 5/13/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe Crypto 9-5 Escape PlanCrypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market InsidersCharles Payne Demystifies OptionsUnstoppable ProsperityElon’s New Device is About to Shock the WorldInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Olema Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
